AIM ImmunoTech (AIM) Competitors $0.12 0.00 (-3.20%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$0.12 +0.00 (+3.31%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AIM vs. AKTX, BLUE, FGEN, ALXO, CVKD, OSTX, IRD, TPST, ESLA, and RVPHShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Akari Therapeutics (AKTX), bluebird bio (BLUE), FibroGen (FGEN), ALX Oncology (ALXO), Cadrenal Therapeutics (CVKD), OS Therapies (OSTX), Opus Genetics (IRD), Tempest Therapeutics (TPST), Estrella Immunopharma (ESLA), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Akari Therapeutics bluebird bio FibroGen ALX Oncology Cadrenal Therapeutics OS Therapies Opus Genetics Tempest Therapeutics Estrella Immunopharma Reviva Pharmaceuticals Akari Therapeutics (NASDAQ:AKTX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Does the media refer more to AKTX or AIM? In the previous week, AIM ImmunoTech had 5 more articles in the media than Akari Therapeutics. MarketBeat recorded 5 mentions for AIM ImmunoTech and 0 mentions for Akari Therapeutics. AIM ImmunoTech's average media sentiment score of 0.29 beat Akari Therapeutics' score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the news media. Company Overall Sentiment Akari Therapeutics Neutral AIM ImmunoTech Neutral Do analysts recommend AKTX or AIM? AIM ImmunoTech has a consensus target price of $2.75, indicating a potential upside of 2,172.73%. Given AIM ImmunoTech's stronger consensus rating and higher possible upside, analysts clearly believe AIM ImmunoTech is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor AKTX or AIM? Akari Therapeutics received 203 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 83.10% of users gave AIM ImmunoTech an outperform vote while only 50.10% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26250.10% Underperform Votes26149.90% AIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90% Which has better earnings & valuation, AKTX or AIM? Akari Therapeutics has higher earnings, but lower revenue than AIM ImmunoTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/AAIM ImmunoTech$190K43.79-$28.96M-$0.31-0.39 Do institutionals and insiders believe in AKTX or AIM? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, AKTX or AIM? Akari Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Is AKTX or AIM more profitable? Akari Therapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Akari Therapeutics' return on equity of 0.00% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A AIM ImmunoTech -12,594.21%-421.73%-147.54% SummaryAIM ImmunoTech beats Akari Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$8.32M$2.97B$5.58B$19.62BDividend YieldN/A1.53%5.35%3.78%P/E Ratio-0.2630.8023.1133.46Price / Sales43.79404.50366.1026.71Price / CashN/A168.6838.1617.54Price / Book0.613.696.684.61Net Income-$28.96M-$72.06M$3.20B$1.02B7 Day Performance-5.39%-6.90%-3.96%-0.77%1 Month Performance0.75%-13.30%1.65%-1.26%1 Year Performance-74.59%-28.40%8.30%4.22% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech2.4211 of 5 stars$0.12-3.2%$2.75+2,172.7%-73.1%$8.32M$190,000.00-0.2620Gap UpAKTXAkari TherapeuticsN/A$1.45-5.2%N/A-27.2%$38.56MN/A0.009Upcoming EarningsAnalyst ForecastGap UpBLUEbluebird bio2.9748 of 5 stars$3.92+0.5%$51.00+1,201.0%-79.2%$38.11M$53.12M-0.10520Analyst ForecastFGENFibroGen4.4516 of 5 stars$0.37+17.1%$10.00+2,610.0%-85.8%$37.24M$29.62M-0.30570Analyst ForecastNews CoverageALXOALX Oncology3.3839 of 5 stars$0.69-2.4%$4.14+499.7%-94.4%$36.85MN/A-0.2340CVKDCadrenal Therapeutics2.5587 of 5 stars$19.50+0.7%$32.00+64.1%N/A$36.66MN/A-2.924Analyst RevisionOSTXOS Therapies1.982 of 5 stars$1.68-2.9%$17.50+941.7%N/A$36.57MN/A0.00N/AAnalyst ForecastGap UpIRDOpus Genetics2.0033 of 5 stars$1.15-8.7%$8.00+595.7%N/A$36.30M$8.38M-1.0614Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading VolumeTPSTTempest Therapeutics3.0087 of 5 stars$0.83+0.4%$26.00+3,051.5%-85.1%$36.01MN/A-0.5420Earnings ReportShort Interest ↓Analyst RevisionESLAEstrella Immunopharma2.0496 of 5 stars$0.99-2.0%$16.00+1,516.5%-34.1%$35.81MN/A-3.81N/ARVPHReviva Pharmaceuticals4.0676 of 5 stars$1.07+2.9%$11.40+965.4%-83.8%$35.78MN/A-0.965Earnings ReportAnalyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies AKTX Alternatives BLUE Alternatives FGEN Alternatives ALXO Alternatives CVKD Alternatives OSTX Alternatives IRD Alternatives TPST Alternatives ESLA Alternatives RVPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AIM Stock Free AIM Stock Alerts